Use of human recombinant erythropoietin for the treatment of nonregenerative anemia in a rough-toothed dolphin (Steno bredanensis).
Erythropoietin, a glycoprotein growth hormone that is produced primarily in the kidneys, promotes mitosis and survival of erythroid progenitors. The recent synthesis of the human form of the hormone by recombinant technology has provided a new therapeutic option, which is being used in both human and veterinary medicine for treatment of various anemias. A mature male rough-toothed dolphin, Steno bredanensis, was treated with human recombinant erythropoietin in an attempt to resolve a nonregenerative anemia. Two i.m. injections 48 hr apart were associated with an almost immediate increase in circulating immature reticulocytes, total reticulocytes, and nucleated erythrocytes. Over the next several weeks, the hematocrit, hemoglobin, and erythrocyte counts returned to normal, and the animal was subsequently released back into the wild. Endogenous erythropoietin concentrations were determined for this animal as well as three other conspecifics by an enzyme-linked immunosorbent assay for human erythropoietin. These measurements showed circulating erythropoietin concentrations (5-20+ mU/ml) similar to those of most other mammals. This study suggests that human recombinant erythropoietin can be safely and effectively used in this species and may have applicability to other cetacean species for the treatment of nonregenerative anemia. Caution should be exercised during long-term use because production of antibodies to human recombinant and endogenous erythropoietin may lead to potentially serious side effects.
Manire
C A
CA
Dolphin and Whale Hospital, Mote Marine Laboratory, Center for Marine Mammal and Sea Turtle Research, Sarasota, Florida 34236, USA.
Rhinehart
H L
HL
D000740:Anemia / Q000188:drug therapy / Q000662:veterinary*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004289:Dolphins; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D004921:Erythropoietin / Q000097:blood / Q000627:therapeutic use*; D005434:Flow Cytometry / Q000662:veterinary; D005839:Gentamicins / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy / Q000662:veterinary; D006400:Hematocrit / Q000662:veterinary; D006417:Hematuria / Q000662:veterinary; D006454:Hemoglobins / Q000032:analysis; D008297:Male; D011507:Proteinuria / Q000662:veterinary; D011899:Ranitidine / Q000627:therapeutic use; D011994:Recombinant Proteins; D012016:Reference Values; D013392:Sucralfate / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D005839:Gentamicins; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D013392:Sucralfate; D011899:Ranitidine